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Abstract
Objective: To estimate the population-level causal effect of source of payment for HIV medication on treatment adherence
using Marginal Structural Models.
Methods: Data were obtained from an observational cohort of 76 HIV-infected individuals with at least 24 weeks of
antiretroviral therapy treatment from 2002 to 2007 in Kampala, Uganda. Adherence was the primary outcome and it was
measured using the 30-day visual analogue scale. Marginal structural models (MSM) were used to estimate the effect of
source of payment for HIV medication on adherence, adjusting for confounding by income, duration on antiretroviral
therapy (ART), timing of visit, prior adherence, prior CD4
+ T cell count and prior plasma HIV RNA. Traditional association
models were also examined and the results compared.
Results: Free HIV treatment was associated with a 3.8% improvement in adherence in the marginal structural model, while
the traditional statistical models showed a 3.1–3.3% improvement in adherence associated with free HIV treatment.
Conclusion: Removing a financial barrier to treatment with ART by providing free HIV treatment appears to significantly
improve adherence to antiretroviral therapy. With sufficient information on confounders, MSMs can be used to make robust
inferences about causal effects in epidemiologic research.
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Introduction
Access to antiretroviral therapy (ART) continues to expand at a
rapid rate [1,2,3]. Of the estimated 9.5 million people in need of
treatment in 2008 in low- and middle-income countries, 42% had
access, up from 33% in 2007 [3]. The greatest progress was seen in
sub-Saharan Africa, where two-thirds of all HIV infections occur.
Prices of the most commonly used antiretroviral drugs have
declined significantly in recent years, contributing to wider
availability of treatment. In most cases ART is provided at no
cost to patients. [3]. There is substantial concern, however, that
there are insufficient resources available to continue the scale-up of
free antiretroviral therapy to all that need it (NYT article on
Uganda, 2009). Insufficient resources for the steady supply of new
patients initiating treatment in most resource-limited settings may
require that patients once again pay for ART. How will the
potential reintroduction of self-pay therapy impact adherence in
settings where there is an inadequate supply of free therapy?
Many studies in resource limited settings have documented that
the cost of medications is a major predictor of non-adherence to
ART [4,5,6,7,8] All these studies were observational in design.
While important associations between variables can be obtained
from observational studies, such studies often are unable to
adequately control for confounding, leading to biased estimates of
causaleffects.Inobservational studies,estimation ofthecausaleffect
of an exposure on an outcome may be biased because of
confounding, i.e. covariates associated with treatment may also be
associated with the potential response, so that the observed response
differences cannot be attributed directly to the exposure. Proper
estimation of causal effects must account for confounding. In studies
where the treatment/exposure does not change (i.e. point
treatment), the traditional method of analysis is to model the
probability of disease as a function of exposure and pretreatment
covariates.However,with atime-varyingexposure,thesetraditional
methods may be biased if time-varying covariates are simulta-
neously confounders and intermediates-that is, if covariates are
predictors of the outcome and also predict subsequent exposure,
and past exposure history predicts resulting covariate level [9]. Such
covariatesarecalled time-dependentconfounders[9],and theypose
unique analytical challenges requiring specialized methods.
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maximum likelihood estimate (MLE) to estimate the causal effect
of source of payment for ART on treatment adherence among
HIV-infected individuals in Kampala, Uganda from 2002 to 2007.
This was a time of rapid transition from exclusively self-pay to free
HIV ART. Marginal structural models (MSMs), developed by
Robins et al [9,10] can obtain causal effect estimates in
observational studies [11,12,13,14], where causal effects are
typically defined as the population exposure of interest changes,
such as payment source of ART from self pay in 2002 to free in
2007. These models are appealing because the coefficients are
directly interpretable causally and they provide unbiased marginal
estimates, even in the presence of time-dependent confounding.
Hence, the aim of this analysis was to estimate the population-level
causal effect of source of payment for ART on treatment
adherence using MSM and to compare the MSM estimate with
estimates from traditional statistical models. MSMs can be used for
causal inference unlike traditional models that suffer confounding
effects.
Materials and Methods
We utilized data from the Adherence Monitoring Uganda
(AMU) study [15,16]. AMU was an observational prospective
cohort study of adherence and treatment response among
individuals on HIV generic antiretroviral therapy conducted from
2002–2007 in Kampala, Uganda. The cohort, assembled from
patients initiating ART from several treatment centers in
Kampala, was comprised of patients on self-pay and those on
free treatment. During the study period some subjects switched
from self-pay to free treatment. Social-demographic characteris-
tics, source of payment for antiretroviral therapy, HIV RNA and
CD4 cell count were obtained prior to initiating antiretroviral
therapy. Participants were then followed prospectively to deter-
mine source of antiretroviral therapy, adherence, HIV RNA, and
CD4 cell count every month for 6 months and then every 3
months for up to 18 months. Antiretroviral adherence was
estimated using 4 measures: 3-day structured self-report (1-
number of doses reported missed/doses prescribed over the prior
3 days), 30-day visual analogue scale (1- percent of pills reported
missed over the last 30 days), electronic medication monitoring
(number of pill bottle openings registered/number of doses
prescribed), and unannounced monthly pill counts (1- number of
pills missing between counts/number of pills prescribed between
counts). Correspondence between the 4 measures was compared.
For this analysis we used the 30-day visual analogue scale
measurements because the other 3 measures were discontinued
after 6 months of follow up for each participant when interim
results showed that all 4 measures were closely correlated with
each other (R=0.77–0.89) [15] At each visit, participants were
asked who paid for their medications. Additional details of the
recruitment and follow-up of patients have been previously
described [15,16].
Statistical analyses
Marginal structural models (MSM) were used to estimate the
difference in adherence means for a given month that would have
been observed between the treatment group (those individuals that
received free therapy) and the control group (those individuals who
paid for their therapy) if source of payment for therapy had been
assigned randomly. The marginal treatment effect is the parameter
of interest. A targeted maximum likelihood estimator (TMLE) was
used to estimate this parameter. A data set was created that
consisted of a data point for each person-month during follow-up
for which source of payment for medication and subsequent
adherence were measured. Confounders considered included prior
adherence, prior CD4 T cell count, prior plasma HIV RNA level,
income, duration on ART and time of visit (period from study
enrolment when study staff visited participant and assessed
adherence).
MSM Assumptions. Several assumptions were made in
order to use the MSM to estimate the parameters of interest.
Counterfactual assumption: we assumed that counterfactuals exist and
that the outcome observed for each patient was one of the
potential outcomes. We thus assumed that this was a missing data
problem. In conjunction with the counterfactual assumption, we
assumed that the treatment or exposure was independent of the
counterfactual outcomes given the covariates (Randomization
assumption). That is, there were no unknown confounders (NUC).
We are not very certain that all confounders were identified.
However, using a directed acyclic graph (DAG) we tried to identify
the important confounders and these were included in the analysis
(Fig. 1). Given that this was a secondary data analysis that was not
planned for when designing the study, many important variables/
confounders may have been missed. Time ordering assumption: The
data collection procedures ensured that the time ordering
assumption was met. That is, the potential confounders for the
relationship between the treatment at a given time, t, and the
outcome at that time existed prior to the treatment.
Correct model specification: The Super Learning procedure was
employed to select the best model [17,18]. Super Learner is a
statistical analysis package that comprises different algorithms and
selects different algorithms for each application. It reduces
variances and improves standard errors. A targeted maximum
likelihood estimator was then used to optimize the bias/variance
tradeoff for the target. Thus, we assume that our model
specification was correct.
Experimental Treatment Assumption (ETA): We assumed that
treatment was not assigned deterministically based on prior
conditions. The probabilities of receiving the treatment were
between 0.2 and 0.6 suggesting that the ETA assumption was met.
Causal effect estimation. The marginal effect of treatment
(causal effect) was estimated by calculating the difference between
1) the mean outcome when all patients was assumed to have been
on free treatment and 2) the mean outcome when all patients was
assumed to be on self-pay treatment. Targeted maximum
likelihood estimation (TMLE) was used to reduce bias in the
parameter of interest [19]. First, the mean of the distribution of the
outcome [adherence at a given visit] was estimated using the
Deletion/Substitution/Addition (DSA) algorithm [17,18]. The
DSA is a data adaptive procedure that employs a cross validation
process on the data where by the data is progressively divided into
training and validation samples. Using DSA based on multivar-
iable logistic regression of source of payment for treatment on
confounders, the probability of receiving the treatment (treatment
mechanism) given one’s covariates was then estimated. Time-
lagged confounder measurements were used to ensure that
confounders occurred before (and, therefore, could not be
influenced by) payment source (Figure 1). HIV RNA values and
income were log transformed. A function of the treatment
mechanism (clever covariate) was then calculated [20]. The clever
covariate for this particular parameter of interest is the inverse
probability of receiving treatment when the treatment is observed
and negative the inverse probability of not receiving treatment
when the treatment is absent. The clever covariate was then used to
target the parameter of interest. The targeting step was performed
by regressing the outcome (adherence at a given visit) on the clever
covariate using the initial estimate of the mean adherence level for
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covariate represents the degree of confounding in the parameter of
interest. The targeting step is repeated until this coefficient is zero.
For this analysis, convergence was attained in one step. Standard
errors for calculating the 95% confidence intervals were estimated
using clustered bootstrap (i.e. randomly sampling patients with
replacement). All analyses were conducted using R software
Version 2.7.2.
Parallel analyses to estimate the effect of treatment were
conducted using generalized estimating equations (GEE) and
ordinary least squares (OLS).
Results
Participant characteristics
Seventy-six participants were included in the analysis with a
total of 251 observations. The 76 participants were observed for a
total of 1669 person-months. Median follow up time was 22
person-months (IQR 18–27). Participants initiated therapy at
advanced stages of HIV infection, with a mean CD4 cell count of
56 cells/ml [SD 130] and median log10 copies RNA/ml of 5.53
(IQR 4.91–5.82). The majority of the cohort was female (63.9%).
The mean age was 36 years (SD 7.5). Fifty-five percent of the
participants earned less than 60 US dollars a month. One third of
the study participants had completed up to a primary level of
education. Details of participant characteristics at study entry have
been published elsewhere [16]. Half of the participants switched
from self-pay to no cost therapy (38/76).
Predictors of treatment
In the model for the treatment mechanism, receiving free
treatment was more likely to occur among individuals with a lower
prior CD4
+ cell count and at later visits (Table 1).
Adherence and source of payment for HIV medication
Overall mean adherence (6 SD) over the course of follow up
was 95.68%616% with a median of 100% (IQR 100%–100%).
Mean adherence in the self-pay person-months was
93.50%619.16% while that in the free person-months was
98.56%69.78% (Figure 2). In the model selected by the DSA
algorithm, current higher adherence was more likely to occur
among patients with a higher rate of prior adherence and those
with lower prior HIV RNA (Table 2).
Applying the targeted maximum likelihood estimator, receiving
free HIV medication was estimated to increase adherence by
3.82% compared to self-pay treatment. This was slightly higher
than the estimates from two traditional association models -
generalized estimating equations (GEE) and ordinary least squares
(OLS) (Table 3).
Discussion
Using a marginal structural model, we estimated a 3.8%
difference in mean adherence when HIV-infected patients receive
free HIV treatment compared to when they pay for the treatment
out-of-pocket. Our finding confirms other studies finding higher
proportion of self-reported adherence [5,8]. In a cohort in
Senegal, adherence rose from 83% to 93% when the cost of
HIV medications was reduced [5]. In Cameroon, Boyer et al
found an inverse relationship between adherence and self-reported
financial difficulties [21]. Weiser and colleagues showed that if cost
was removed as a barrier to adherence, the proportion of adherent
individuals in Botswana would increase from 54% to 74%] [8].
While all of these studies, including our study, were observational
studies, there are some important differences to note. The
Botswana and Cameroon studies were cross sectional in design
and provide more limitations in their causal inference. Our study
employed a marginal structural model for analysis while the other
Figure 1. Directed acyclic graph (causal diagram).
doi:10.1371/journal.pone.0070375.g001
Table 1. Multivariable regression model of source of
payment for HIV medication on confounders.
Term in multivariable logistic regression
model OR (95%CI)
Prior adherence 1.002 (0.983 to 1.021)
Prior HIV RNA
a 1.042 (0.878 to 1.235)
Prior CD4
+ cell count 0.998 (0.997 to 0.999)
Income
a 0.971 (0.906 to 1.041)
Duration on ART 1.000 (0.998 to 1.003)
Time of visit 1.905 (1.333 to 2.722)
NOTE: Model was selected using cross-validated deletion/substitution/addition
algorithm.
alog transformed.
doi:10.1371/journal.pone.0070375.t001
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can be made with MSMs unlike traditional models that suffer
confounding effects.
The MSM is a semi-parametric model whose validity depends
on meeting specific assumptions. However, some of the assump-
tions cannot be tested from the data. Non-testable assumptions are
the time ordering and the counterfactual assumptions. Neverthe-
less, we are certain that the time ordering assumption was met
because three of the authors participated in the design and
implementation of the study. We are not very certain that the
randomization assumption was met given the limited number of
confounders that were collected. Statistical analysis showed that
the ETA assumption was met. We believe that our model was
correctly specified because we employed Super Learner which is the
best approach for selecting big models.
All participants in this analysis initiated ART with advanced
disease. This was not intentional by the investigators neither was it
a choice of the patients. At the time of enrolment of patients into
this study, HIV drugs were not readily available and they were
very costly. Those few who could access them were supported by
family and friends through huge financial sacrifices. As such these
patients initiated treatment very late as sustainability of treatment
was not guaranteed. However later in the course of the study, the
government of Uganda gradually introduced free ART for all HIV
patients. Because of the large number of patients, poorer and
sicker patients (as per their CD4 count) were often given priority
over their fellow patients with slightly better immunity. Another
cause for late initiation of ART was stigma. Patients did not want
to be identified as HIV positive hence kept away from care until
very late when there was no choice but to show up if they wanted
Figure 2. Comparing mean adherence rates for person-months on self-pay treatment and person-months on free treatment.
doi:10.1371/journal.pone.0070375.g002
Table 2. Multivariable regression model of adherence percentage on source of payment for HIV medication and confounders.
Term in multivariable linear regression model Coefficient (95%CI)
Source of payment for HIV medication 3.332 (20.575 to 7.239)
Prior adherence 0.232 (0.107 to 0.357)
Prior HIV RNA
a 21.413 (22.546 to 20.279)
Prior CD4
+ cell count 20.003 (20.014 to 0.007)
Income
a 0.054 (20.406 to 0.514)
Duration on ART 0.003 (20.014 to 0.020)
Time of visit 1.337 (20.964 to 3.637)
NOTE: Model was selected using cross-validated deletion/substitution/addition algorithm.
alog transformed.
doi:10.1371/journal.pone.0070375.t002
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affected by selection bias given that the majority of the study
participants were of a low social economic class and hence could
not afford medications which consequently led to switch to free
ART with priority. However, a qualitative study conducted in the
same population to understand how and why the patients had
exceptional adherence revealed that the main reason for adhering
to ARV medications was the desire to live and take care of other
family members [22]. This factor surpassed any other reason.
Despite financial constraints, participants rarely reported missing a
dose of antiretroviral medication. However, they described this
excellent adherence as the product of a constant battle to
overcome the barrier of drug cost.
Our analysis using traditional models gave effects of 3.3% and
3.1% using a repeated measures model and the ordinary least
squares model respectively. These effect sizes were less than the
one from the MSM, underestimating the net effect of payment
source on adherence, with the estimate from the ordinary least
squares models failing to meet statistical significance (95% CI
20.57 to 7.24) Other analyses have shown greater attenuation of
effects and even reversal of effects when using traditional statistical
models [23,24]. The 95% confidence intervals for estimates from
all three models [including the MSM] were wide suggesting that
the study had a small sample size. The small sample was
nevertheless adequately powered to detect the difference with
statistical significance [with the MSM and GEE] implying that an
association truly exists between source of payment for ART and
ART adherence. Larger studies may need to be conducted to
establish the precision of this estimate.
There are several of limitations to our study. Our study was
conducted among a small sample of ARV-naı ¨ve individuals who
initiated treatment at an advanced stage of disease. This may limit
generalizability of the findings. Although the analysis showed a
significant association between source of payment for ART and
adherence, there is a possibility that the results could have been
biased. The following biases may have occurred although the
extent of bias cannot be quantified. Selection bias is very likely to
have influenced the results. Study participants were recruited from
health facilities in Kampala. However, because of the extent of
stigma that many HIV patients suffered at that time, many
patients, especially those who could afford to purchase their
medications, preferred to meet their care givers in private or to just
send another person to the health facility to refill their
prescriptions. Consequently, patients that were recruited in the
study may not have been representative of all HIV-infected
patients who were on ART. As such, the odds of selection for the
exposed (those on free-pay) were not equal to the odds of selection
for the non-exposed (those on self- pay) hence selection bias. There
was an over representation of exposed non-cases (adherent)
compared to the non-exposed cases (non-adherent). Information
bias was another possible bias. This could have occurred as a result
of loss to follow up as 50% of the patients who died (10% of those
enrolled) died within 6 months of initiating ART and the majority
of these were on self-pay treatment [16]. Another source of
information bias may have been due to end-digit-preference in
estimating adherence using the visual analogue scale. That is,
someone would rather report 80% than 73% or 77%. While the
VAS was closely associated with viral suppression and other
measures of adherence in this setting, it has performed variably
well in other contexts [15,25,26,27]. Confounding bias is also
possible in that we did not consider all the possible factors that
could likely distort the true relationship between the main
predictor and outcome. Possible confounding factors not consid-
ered were state of depression and level of education. We did not
explore in detail the inherent difference between exposed patients
and non-exposed patients irrespective of how they obtained their
medications. Patients who paid for their medications may have
been different in significant ways from those who received free
treatment. We had an insufficient number of HIV RNA
determinations to estimate the impact of payment source on viral
suppression.
Though useful in establishing causality, the marginal structural
model has limitations. It makes the strong assumption of no
unmeasured confounders. Causal effects can be estimated from the
MSM parameters only if all relevant covariates are measured in
the data and are adequately controlled in the analysis, including
having appropriate models for determining the treatment mech-
anism and consequently the clever covariate which targets the
parameter of interest. The MSM can correctly adjust for measured
time-varying confounders that are affected by exposure. Given
that this was a secondary data analysis that was not planned for
when the study was designed, all confounding factors may not
have been included in the analysis thus compromising the validity
of our findings.
Our study also had several strengths. The study was conducted
at a time when the healthcare system in Uganda was transitioning
from self-pay to free treatment, which provided a ‘‘natural
experiment’’ for study. It would be unethical at the present time
to conduct a randomized trial to answer the question addressed in
this analysis. Furthermore, state-of-the-art data analyses and the
use of alternative methods to control for confounding improved
the robustness of the findings.
In summary, we found that receiving free HIV treatment was
associated with better adherence among low income HIV-infected
patients in a resource-limited setting. In a separate qualitative
study conducted in the same population, lack of enough finances
to purchase medications was reported as the main reason for
missing doses [22]. Our findings are useful in the ongoing
discussion on the feasibility of continuing free therapy and related
debates as to whether user fees should be introduced in resource-
limited settings. There is broad consensus that user fees are an
important barrier to accessing health services, especially for poor
people [28,29,30]. Increasing the cost of care is likely to lower
adherence and introduce the possibility of rationing and/or
sharing drugs among HIV-infected family members. User fees to
secure ART will add to existing structural-economic barriers to
care, such as transportation and lost income production, which are
significant barriers even with free ART [4,31,32]. Increasing the
Table 3. Marginal structural model estimates vs. Traditional
model estimates of the effect of source of payment for HIV
medication on adherence.
Method
Difference in mean adherence
(95% CI)
Marginal Structural Model 3.82 (0.97–6.66)
Generalized Estimating Equations
Crude 6.26 (2.66–9.85)
Adjusted* 3.10 (0.95–5.24)
Ordinary Least Squares
Crude 5.06 (1.09–9.04)
Adjusted* 3.33 (20.57–7.24)
*adjusted for income, duration on ART, prior adherence, prior CD4+ T cell count,
prior HIV RNA.
doi:10.1371/journal.pone.0070375.t003
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compromise the dramatic success of the ART scale up to date.
Further research is needed to understand how adherence changes
over time when patients are on free or subsidized treatment. Once
the cost factor is removed from the adherence equation, what are
the other modifiable factors that influence adherence?
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